ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Epithelial tumor cells that have undergone epithelial-to-mesenchymal transition (EMT) are typically prone to metastasis and drug resistance and contribute to a poor clinical outcome. The transcription factor ZEB1 is a known driver of EMT, and mediators of ZEB1 represent potential therapeutic targets for metastasis suppression. Here, we have shown that phosphatidylinositol 3-kinase-targeted (PI3K-targeted) therapy suppresses metastasis in a mouse model of Kras/Tp53-mutant lung adenocarcinoma that develops metastatic disease due to high expression of ZEB1. In lung adenocarcinoma cells from Kras/Tp53-mutant animals and human lung cancer cell lines, ZEB1 activated PI3K by derepressing miR-200 targets, including amphiregulin (AREG), betacellulin (BTC), and the transcription factor GATA6, which stimulated an EGFR/ERBB2 autocrine loop. Additionally, ZEB1-dependent derepression of the miR-200 and miR-183 target friend of GATA 2 (FOG2) enhanced GATA3-induced expression of the p110α catalytic subunit of PI3K. Knockdown of FOG2, p110α, and RHEB ameliorated invasive and metastatic propensities of tumor cells. Surprisingly, FOG2 was not required for mesenchymal differentiation, suggesting that mesenchymal differentiation and invasion are distinct and separable processes. Together, these results indicate that ZEB1 sensitizes lung adenocarcinoma cells to metastasis suppression by PI3K-targeted therapy and suggest that treatments to selectively modify the metastatic behavior of mesenchymal tumor cells are feasible and may be of clinical value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 3×
“In the “migrating stem cell hypothesis,” metastases arise from a small population of tumor cells with the capacity to undergo epithelial-mesenchymal transition (EMT), a reversible process characterized by a loss of polarized features, detachment from neighboring cells, increased motility and invasion, and resistance t…”
Gene-expression profiles predict survival of patients with lung adenocarcinoma
Beer, D. G., Kardia, S. L. R., Huang, C.-C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., et al. (2002) · Nature Medicine · doi:10.1038/nm733 · Cited by 2,025
Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Self-citationIliopoulos, D., Lindahl-Allen, M., Polytarchou, C., Hirsch, H. A., Tsichlis, P. N., & Struhl, K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.013 · Cited by 399 · cited 1×
“Targets of the miR-200 family include SOX2, KLF4, BMI1, and SUZ12, which function as master regulators of cell specification during embryonic development (10, 43).”
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Navas, C., Hernández-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C., & Barbacid, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.001 · Cited by 391 · cited 1×
“In mice that develop KRAS-mutant human pancreatic tumors, EGFR activates PI3K and is required for tumor outgrowth (41).”
Botling, J., Edlund, K., Lohr, M., Hellwig, B., Holmberg, L., Lambe, M., Berglund, A., Ekman, S., Bergqvist, M., Pontén, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1139 · Cited by 359
Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210
Cited by
Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 966
Self-citationZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
Zhang, P., Sun, Y., & Ma, L. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1006048 · Cited by 611
“Mechanistically, ZEB1 activates PI3K by derepressing miR-200 and miR-183 targets, including amphiregulin (AREG), betacellulin (BTC), the transcription factor GATA6 and friend of GATA 2 (FOG2).(70) FOG2 mediates ZEB1induced expression of the p110a catalytic subunit of PI3K, but surprisingly, FOG2 is not required for ZE…”
BackgroundCircNet: a database of circular RNAs derived from transcriptome sequencing data
Liu, Y.-C., Li, J.-R., Sun, C.-H., Andrews, E., Chao, R.-F., Lin, F.-M., Weng, S.-L., Hsu, S.-D., Huang, C.-C., Cheng, C., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv940 · Cited by 343
ZEB1 drives epithelial-to-mesenchymal transition in lung cancer
Larsen, J. E., Nathan, V., Osborne, J. K., Farrow, R. K., Deb, D., Sullivan, J. P., Dospoy, P. D., Augustyn, A., Hight, S. K., Sato, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci76725 · Cited by 334
Self-citationEGF receptor ligands: recent advances
Singh, B., Carpenter, G., & Coffey, R. J. (2016) · F1000Research · doi:10.12688/f1000research.9025.1 · Cited by 323
Metadata
- Authors
- Yang, Y., Ahn, Y.-H., Chen, Y., Tan, X., Guo, L., Gibbons, D. L., Ungewiss, C., Peng, D. H., Liu, X., Lin, S. H., Thilaganathan, N., Wistuba, I. I., Rodriguez-Canales, J., McLendon, G., Creighton, C. J., & Kurie, J. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-04-24
- Volume
- 124
- Issue
- 6
- Pages
- 2696-2708
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2165903333
- Cited by
- 115
- References
- 8
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. https://app.cochat.ai/papers/10.1172/jci72171
- The paper
- Yang, Y., Ahn, Y.-H., Chen, Y., Tan, X., Guo, L., Gibbons, D. L., Ungewiss, C., Peng, D. H., Liu, X., Lin, S. H., Thilaganathan, N., Wistuba, I. I., Rodriguez-Canales, J., McLendon, G., Creighton, C. J., & Kurie, J. M. (2014). ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. Journal of Clinical Investigation. https://doi.org/10.1172/jci72171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.